Antiretroviral Management of Treatment-Naive Patients

Infectious Disease Clinics of North America

Volumn 21, Issue 1, 2007, Pages 71-84

  Gulick, Roy M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LOW DRUG DOSE; LUNG DISEASE; PRACTICE GUIDELINE; RASH; REVIEW; SYMPTOMATOLOGY;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 34248198837     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2007.01.002     Document Type: Review

References (54)

1. Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: www.aidsinfo.org. Accessed October 10, 2006.
2. Hammer S.M., Squires K.E., Hughes M.D., et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 337 (1997) 725-733
3. Cameron D.W., Heath-Chiozzi M., Danner S., et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 351 (1998) 543-549
4. Phillips A., and CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 18 (2004) 51-58
5. Egger M., May M., Chene G., et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360 (2002) 119-129
6. 6/L. AIDS 16 (2000) 1371-1381
7. Wang C., Vlahov D., Galai N., et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 190 (2004) 1046-1054
8. Sterne J, May M, Costagliola D, et al. Estimating the optimum CD4 threshold for starting HAART in ART-naive HIV-infected individuals [abstract #525]. Abstracts presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver (CO), February 5-8, 2006.
9. Lichtenstein K, Armon C, Buchacz K, et al. Early, uninterrupted ART is associated with improved outcomes and fewer toxicities in the HIV Outpatient Study (HOPS) [abstract #769]. Abstracts presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver (CO), February 5-8, 2006.
10. Hammer S.M., Saag M.S., Schechter M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296 (2006) 827-843
11. Eron J.J., Benoit S.L., Jemsek J., et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 333 (1995) 1662-1669
12. Gulick R.M., Mellors J.W., Havlir D., et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337 (1997) 734-739
13. Saag M.S., Tebas P., Sension M., et al. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS 15 (2001) 1971-1978
14. Staszewski S., Morales-Ramirez J., Tashima K.T., et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 341 (1999) 1865-1873
15. Murphy R, DaSilva BA, Hicks CB, et al. Seven year follow-up of a lopinavir/ritonavir (LPV/r)-based regimen in antiretroviral (ARV)-naive subjects [abstract # PE7.9/3]. Abstracts presented at the 10th European AIDS Conference (EACS). Dublin (Ireland), November 17-20, 2005.
16. Walmsley S., Bernstein B., King M., et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346 (2002) 2039-2046
17. van Leth F., Phanuphak P., Ruxrungtham K., et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363 (2004) 1253-1263
18. Gallant J.E., Staszewski S., Pozniak A.L., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292 (2004) 191-201
19. van Leeuwen R., Katlama C., Murphy R.L., et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 17 (2003) 987-999
20. Robbins G.K., De Gruttola V., Shafer R.W., et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349 (2003) 2293-2303
21. Bartlett J.A., Johnson J., Herrera G., et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defic Syndr 43 (2006) 284-292
22. Gathe Jr. J.C., Ive P., Wood R., et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 18 (2004) 1529-1537
23. Eron Jr. J., Yeni P., Gathe Jr. J., et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368 (2006) 476-482
24. DeJesus E., Herrera G., Teofilo E., et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 39 (2004) 1038-1046
25. Clay P.G. The abacavir hypersensitivity reaction: a review. Clin Ther 24 (2002) 1502-1514
26. *5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359 (2002) 727-732
27. Eron J.J., Feinberg J., Kessler H.A., et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis 189 (2004) 265-272
28. Gallant J.E., DeJesus E., Arribas J.R., et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354 (2006) 251-260
29. Pozniak A.L., Gallant J.E., Dejesus E., et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 43 (2006) 535-540
30. Montaner J.S., Reiss P., Cooper D., et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 279 (1998) 930-937
31. Podzamczer D., Ferrer E., Consiglio E., et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 7 (2002) 81-90
32. Baylor M.S., and Johann-Liang R. Hepatotoxicity associated with nevirapine use. [letter]. J Acquir Immune Defic Syndr 35 (2004) 538-539
33. Gulick R.M., Ribaudo H.J., Shikuma C.M., et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 350 (2004) 1850-1861
34. Gulick R.M., Ribaudo H.J., Shikuma C.M., et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 296 (2006) 769-781
35. Palella Jr. F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 (1998) 853-860
36. Squires K., Lazzarin A., Gatell J.M., et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 36 (2004) 1011-1019
37. Malan N, Krantz E, David N, et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089 [abstract #107LB]. Abstracts presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver (CO), February 5-8, 2006.
38. Chou R., Fu R., Huffman L.H., et al. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 368 (2006) 1503-1515
39. Bartlett J.A., Fath M.J., Demasi R., et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 20 (2006) 2051-2064
40. Riddler SA, Haubrich R, DiRienzo G, et al. A prospective, randomized, phase III trial of NRTI-, PI- and NNRTI-sparing regimens for initial treatment of HIV-1 infection-ACTG 5142 [abstract #ThLB0204]. Abstracts presented at the XVI International AIDS Conference. Toronto (Canada), August 13-18, 2006.
41. Staszewski S., Keiser P., Montaner J., et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 285 (2001) 1155-1163
42. Vibhagool A., Cahn P., Schechter M., et al. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naive adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr Med Res Opin 20 (2004) 1103-1114
43. Kumar P.N., Rodriguez-French A., Thompson M.A., et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med 7 (2006) 85-98
44. Gallant J.E., Rodriguez A.E., Weinberg W.G., et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 192 (2005) 1921-1930
45. Khanlou H., Yeh V., Guyer B., et al. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS 19 (2005) 135-140
46. Moyle G., Higgs C., Teague A., et al. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther 11 (2006) 73-78
47. Gathe JC, Washington MY, Mayberry C, et al. IMANI-1 TC3WP Single drug HAART- proof of concept study. Pilot study of the safety and efficacy of Kaletra (LPV/r) as single drug HAART in HIV + ARV-naive patients-interim analysis of subjects completing final 48 week data [abstract # MoOrB1057]. Abstracts presented at the XIV International AIDS Conference. Bangkok (Thailand), July 11-16, 2004.
48. Delfraissy J-F, Flandre P, Delaugerre C, et al. MONARK trial (MONotherapy AntiRetroviral Kaletra): 48-week analysis of lopinavir/ritonavir (LPV/r) monotherapy compared to LPV/r + zidovudine/lamivudine (AZT/3TC) in antiretroviral-naive patients [abstract #THLB0202]. Abstracts presented at the XVI International AIDS Conference. Toronto (Canada), August 13-18, 2006.
49. Shafer R.W., Smeaton L.M., Robbins G.K., et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349 (2003) 2304-2315
50. INITIO Trial International Co-ordinating Committee, Yeni P., Cooper D.A., Aboulker J.P., et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 368 (2006) 287-298
51. Van den Berg-Wolf M, Peng G, Xiang Y, et al. Efficacy and safety of nevirapine versus efavirenz when combined in ART regimens in HIV-infected antiretroviral-naive persons (the NNRTI substudy of FIRST-CPCRA 058) [abstract # THPE0104]. Abstracts presented at the XVI International AIDS Conference. Toronto (Canada), August 13-18, 2006.
52. Greaves W, Landovitz R, Fatkenheuer G, et al. Late virologic breakthrough in treatment-naive patients on a regimen of combivir + vicriviroc [abstract #161LB]. Abstracts presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver (CO), February 5-8, 2006.
53. Pfizer Press Release, January 24, 2006.
54. Markowitz M, Nguyen B-Y, Gotuzzo F, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naive HIV-1 infected patients [abstract # THLB0214]. Abstracts presented at the XVI International AIDS Conference. Toronto (Canada), August 13-18, 2006.